Kensey Nash Corp. (NSDQ:KNSY) entered into a manufacturing deal with London-based Orteq Sports Medicine that includes a minority equity investment in the company.
Orteq filed with the Food & Drug Administration for approval of a clinical trial on its Actifit bio-compatible synthetic meniscal repair scaffold, and if the agency approves the trial, Kensey Nash will invest an additional $1 million in Orteq. The device is already available in Europe.